 |
| 14-May-13 | Reiterated |
Stifel |
Buy |
$44 → $54 |
|
| 18-Apr-13 | Reiterated |
Stifel |
Buy |
$37 → $44 |
|
| 12-Feb-13 | Initiated |
Robert W. Baird |
Outperform |
$27 |
|
| 12-Mar-12 | Initiated |
Brean Murray |
Buy |
$24 |
|
| 03-Jun-11 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$30 → $23 |
|
| 29-Mar-10 | Initiated |
Piper Jaffray |
Overweight |
$16 |
|
| 29-Jan-10 | Reiterated |
Credit Suisse |
Neutral |
$18 → $17 |
|
| 20-Feb-09 | Initiated |
ThinkEquity |
Buy |
$23 |
|
| 13-Feb-09 | Reiterated |
Credit Suisse |
Neutral |
$14 → $18 |
|
| 05-Feb-09 | Upgrade |
Robert W. Baird |
Neutral → Outperform |
$15 → $23 |
|
| 20-Nov-08 | Reiterated |
Stanford Research |
Buy |
|
|
| 29-Oct-08 | Downgrade |
Credit Suisse |
Outperform → Neutral |
$18 → $10 |
|
| 05-Sep-08 | Initiated |
Susquehanna Financial |
Positive |
|
|
| 04-Mar-08 | Reiterated |
Stanford Research |
Buy |
$34 → $26 |
|
| 04-Mar-08 | Reiterated |
Lehman Brothers |
Equal-weight |
$21 → $15 |
|
| 15-Jan-08 | Initiated |
Robert W. Baird |
Neutral |
$22 |
|
| 26-Oct-07 | Upgrade |
Stanford Research |
Hold → Buy |
$34 |
|
| 21-Aug-07 | Initiated |
Cowen & Co |
Outperform |
|
|
| 27-Apr-07 | Initiated |
Credit Suisse |
Outperform |
$39 |
|
| 09-Feb-07 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$34 → $46 |
|
|
|
| 18-Jun-13 06:58PM | Is Elan Pushing Its Luck? at Motley Fool |
| 01:29PM | Royalty Pharma abandons bid for Elan at Financial Times |
| 08:56AM | Royalty drops hostile bid for Ireland's Elan Reuters |
| 17-Jun-13 06:49PM | Elan holders OK buyback, vote down 3 deals AP |
| 04:39PM | Theravance Larger Than S&P 500 Component E*trade Financial Corporation at Forbes |
| 04:05PM | Elan Investors Approve Buyback to Force Royalty Bid End at Bloomberg |
| 04:00PM | Elan Explores Sale Options Zacks |
| 01:45PM | Elan Shareholders Bring Management To Heel at Investopedia |
| 01:32PM | Theravance Will Split Into 2 Companies After Losing Elan Bid at Motley Fool |
| 01:11PM | Elan holders OK buyback, vote down 3 deals AP |
| 10:13AM | Theravance to proceed with plan to split business AP |
| 08:18AM | Elan Shareholders Do Not Approve Theravance/Elan Royalty Participation Transaction Marketwired |
| 08:09AM | Elan holders OK buyback, vote down 3 deals AP |
| 07:44AM | Elan Shareholder Vote Nixes Royalty Pharma Takeover -- For Now at TheStreet |
| 06:53AM | Royalty hostile bid for Elan in doubt after vote Reuters |
| 06:53AM | Elan holders OK buyback, vote down 3 deals AP |
| 06:52AM | Elan holders OK buyback, vote down 3 deals AP |
| 06:35AM | Elan shareholders approve buyback in blow to Royalty bid Reuters |
| 06:33AM | Elan Investors Approve Buyback to Force Royalty Bid End at Bloomberg |
| 01:51AM | THERAVANCE INC Files SEC form 8-K, Other Events EDGAR Online |
| 14-Jun-13 07:00PM | Elan Inviting Royalty Pharma Bid Shows Hostility Easing at Bloomberg |
| 01:00PM | Elan Relents And Goes On Sale; Stock Pops at Investor's Business Daily |
| 12:52PM | Drugmaker Elan plans to explore sale of company AP |
| 10:36AM | Drugmaker Elan plans to explore sale of company AP |
| 04:24AM | Elan Rises as Most Investors Reject Three Bid-Hald Plans at Bloomberg |
| 13-Jun-13 05:01PM | Theravance Inc. (THRX): Today's Featured Drugs Laggard at TheStreet |
| 03:43PM | Theravance's Management Presents at Goldman Sachs Healthcare Conference (Transcript) at Seeking Alpha |
| 10:22AM | Elan Drops as Royal Pharma Says Takeover May Fail at Bloomberg |
| 03:36AM | Divisive Elan boss Martin faces ownership showdown Reuters |
| 11-Jun-13 04:10PM | Royalty pursuing hostile bid for Elan, fights Irish panel ruling Reuters |
| 03:33PM | Royalty pursuing hostile bid for Elan, fights Irish panel ruling Reuters |
| 10:00AM | Elan's share buyback in focus as it fights $8 billion takeover at Reuters |
| 10-Jun-13 07:15PM | Elan rejects Royalty bid, to evaluate other offers AP |
| 05:59PM | Elan's share buyback in focus as it fights $8 billion takeover at Reuters |
| 05:52PM | DEALTALK-Elan's share buyback in focus as it fights $8 bln takeover at Reuters |
| 03:17PM | Elan rejects Royalty bid, to evaluate other offers AP |
| 01:00PM | AstraZeneca Pays Up To Patch Up Another Key Area at Investopedia |
| 11:33AM | AstraZeneca Buying Pearl As COPD Drug Race Heats Up at Investor's Business Daily |
| 09:33AM | Elan rejects Royalty bid, to evaluate other offers AP |
| 09:10AM | Elan rejects Royalty bid, to evaluate other offers AP |
| 05:35AM | Elan tells advisors to assess all strategic interests theflyonthewall.com |
| 02:32AM | Elan Board Rejects $6.7 Billion Royalty Pharma Offer at Bloomberg |
| 07-Jun-13 04:04PM | Royalty Pharma Raises Elan Offer to $6.7 Billion Plus CVR at Bloomberg |
| 03:01PM | Royalty Pharma raises bid for Elan to potential $8 billion Reuters |
| 09:44AM | [video] Faber: Royalty Pharma Increases Bid for Elan at CNBC |
| 07:12AM | Royalty Pharma Raises Elan Offer to $6.7 Billion Plus CVR at Bloomberg |
| 06-Jun-13 04:22PM | Elan Finds Creative Poison Pill to Defend Against a Hostile Bid at New York Times |
| 04:06PM | Royalty Pharma Extends $6.4 Billion Elan Takeover Offer at Bloomberg |
| 01:45PM | Ruling threatens Royalty Pharma's Elan bid ahead of key meeting at Reuters |
| 09:04AM | Investors Should Vote 'No' on Billion-Dollar Deal at Motley Fool |
| 03:28AM | Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash at Bloomberg |
| 04-Jun-13 04:44PM | Judge halts Royalty Pharma's bid for Elan stock AP |
| 04:41PM | InPlay: Theravance calls for redemption of $172.5 mln of 3% Convertible Subordinated Notes due 2015 Briefing.com |
| 04:40PM | Theravance, Inc. Calls for Redemption of $172.5 Million of 3% Convertible Subordinated Notes Due 2015 (CUSIP No. 88338T AA2) Marketwired |
| 04:40PM | Theravance, Inc. Calls for Redemption of $172.5 Million of 3% Convertible Subordinated Notes Due 2015 (CUSIP No. 88338T AA2) Marketwire |
| 12:08PM | U.S. court freezes Royalty's bid for drugmaker Elan Reuters |
| 10:46AM | Judge halts Royalty Pharma's bid for Elan stock AP |
| 10:15AM | THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 07:54AM | Royalty Pharma Takeover of Elan Temporarily Blocked at Bloomberg |
| 03-Jun-13 08:22PM | Irish, U.S. courts temporarily stop Royalty's bid for Elan at Reuters |
| 10:45AM | THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online |
| 31-May-13 03:47PM | 3 Top Pharma Stock Picks for the Long Term at Motley Fool |
| 30-May-13 01:17PM | Royalty CEO Says Investors Signaled Support for Elan Bid at Bloomberg |
| 09:19AM | Elan CEO Says Alternatives Exist If Shareholders Reject Deals at Bloomberg |
| 08:31AM | Elan says has "Plan B" if shareholders reject deals at Reuters |
| 29-May-13 07:01PM | Royalty CEO Says Investors Signaled Support for Elan Bid at Bloomberg |
| 24-May-13 03:30PM | Elan Rejects Royalty Offer Again Zacks |
| 11:45AM | Royalty Pharma offer for Elan gets little support AP |
| 23-May-13 05:17PM | Royalty Pharma eases condition for Elan offer AP |
| 04:05PM | Theravance to Present at Investor Conferences in June 2013 Marketwired |
| 04:05PM | Theravance to Present at Investor Conferences in June 2013 Marketwire |
| 04:04PM | Elan Board Unanimously Rejects $6.4 Billion Takeover Offer at Bloomberg |
| 01:36PM | Elan rejects Royalty's $6.4 billion raised offer Reuters |
| 01:22PM | Elan rejects Royalty's $6.4 bln raised offer at Reuters |
| 08:06AM | Royalty Pharma eases condition for Elan offer AP |
| 08:01AM | Royalty cuts acceptance bar for Elan bid to 50 percent at Reuters |
| 08:00AM | Royalty cuts acceptance bar for Elan bid to 50 pct at Reuters |
| 21-May-13 06:30PM | When Savvy Dealmaking Borders on Reckless Spending at Motley Fool |
| 03:46PM | Elan Provides Strategic Update Zacks |
| 03:13PM | Analysts: Microsoft Has Big Potential and 3 More Research Notes to Browse at Wall St. Cheat Sheet |
| 01:30PM | Elan Continues To Make Baffling Strategic Decision at Investopedia |
| 10:02AM | THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 07:07AM | Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray at theflyonthewall.com |
| 20-May-13 06:06PM | Nasdaq stocks posting largest percentage decreases AP -6.52% |
| 04:05PM | Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash at Bloomberg |
| 03:27PM | Royalty raises Elan bid, issues ultimatum to shareholders at Reuters |
| 02:33PM | Royalty Pharma increases bid for drugmaker Elan AP |
| 02:00PM | The 3 Deadliest Diseases in the U.S. at Motley Fool |
| 01:17PM | Nasdaq stocks posting largest percentage decreases AP |
| 12:01PM | Royalty Pharma Raises Elan Bid to $12.50 a Shae in Cash at Bloomberg |
| 10:02AM | THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 03:35AM | Elan Makes Two Acquisitions for $380 Million at Bloomberg |
| 02:14AM | THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 18-May-13 01:45PM | This Week in Biotech at Motley Fool |
| 17-May-13 11:27AM | The Billion Dollar COPD Deal: Who Gains The Most? at Seeking Alpha |
| 16-May-13 03:39PM | A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical Companies Wall Street Transcript |
| 09:30AM | THERAVANCE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 15-May-13 07:26PM | Theravance's CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha |
| 01:42PM | Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies at Motley Fool |
| 14-May-13 04:00PM | Elan in Royalty Deal with THRX Zacks |
|
|
| Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. The company's respiratory programs with GlaxoSmithKline plc include RELVAR or BREO, an inhaled corticosteroid/long-acting beta2 agonist combination treatment, comprising fluticasone furoate and vilanterol (VI), for the treatment of chronic obstructive pulmonary disease (COPD) and asthma; ANORO, a once-daily investigational medicine, combining a long-acting muscarinic antagonist (LAMA), umeclidinium, and a LABA, VI, for the treatment of COPD; and GSK961081, an investigational, single molecule bifunctional bronchodilator with both muscarinic antagonist and beta2 receptor agonist activities. Its bacterial infections program includes VIBATIV for the treatment of nosocomial pneumonia; and its CNS/pain programs consist of TD-1211, a multivalent inhibitor of the mu opioid receptor for alleviating gastrointestinal side effects of opioid therapy without affecting analgesia, and TD-9855, which is in Phase II study in adults with attention-deficit/hyperactivity disorder and fibromyalgia. The company's theravance respiratory program includes TD-4208, an investigational inhaled LAMA in Phase IIb study to evaluate the safety and pharmacokinetics of multiple doses; and gastrointestinal motility dysfunction program consists of Velusetrag, an oral, investigational medicine dosed once-daily in Phase II proof-of-concept study to evaluate velusetrag for the treatment of patients with diabetic or idiopathic gastroparesis through collaboration with Alfa Wassermann. It also has collaborations with Merck & Co. and R-Pharm CJSC. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Shafer Bradford J | Sr VP, Gen. Counsel, Secretary | Jun 07 | Sale | 35.04 | 31,038 | 1,087,572 | 303,416 | Jun 11 07:02 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | May 29 | Option Exercise | 8.54 | 11,021 | 94,159 | 213,705 | May 31 07:03 PM | | Brinkley David L | Head of Business Dev. | May 29 | Sale | 35.01 | 3,808 | 133,318 | 48,749 | May 31 07:02 PM | | Brinkley David L | Head of Business Dev. | May 13 | Option Exercise | 34.00 | 16,129 | 548,386 | 71,129 | May 15 07:07 PM | | Brinkley David L | Head of Business Dev. | May 13 | Sale | 40.33 | 16,129 | 650,483 | 55,000 | May 15 07:07 PM | | Brinkley David L | Head of Business Dev. | May 03 | Option Exercise | 29.65 | 16,129 | 478,225 | 71,129 | May 07 07:01 PM | | Brinkley David L | Head of Business Dev. | May 03 | Sale | 34.77 | 16,129 | 560,805 | 55,000 | May 07 07:01 PM | | Winningham Rick E | Chief Executive Officer | Apr 30 | Option Exercise | 9.69 | 385,161 | 3,731,247 | 977,083 | May 02 07:00 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Apr 30 | Option Exercise | 17.91 | 170,879 | 3,060,443 | 313,365 | May 02 07:04 PM | | Brinkley David L | Head of Business Dev. | Apr 30 | Option Exercise | 6.15 | 8,333 | 51,248 | 72,104 | May 02 07:05 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Apr 30 | Sale | 33.80 | 170,879 | 5,776,341 | 142,486 | May 02 07:04 PM | | Winningham Rick E | Chief Executive Officer | Apr 30 | Sale | 33.64 | 255,532 | 8,597,169 | 721,551 | May 02 07:00 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Apr 30 | Sale | 33.74 | 7,000 | 236,164 | 205,976 | May 02 07:06 PM | | Brinkley David L | Head of Business Dev. | Apr 30 | Sale | 33.76 | 17,104 | 577,490 | 55,000 | May 02 07:05 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Feb 20 | Sale | 22.14 | 7,000 | 154,980 | 212,976 | Feb 22 07:03 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Jan 11 | Option Exercise | 3.10 | 14,510 | 44,981 | 220,438 | Jan 14 07:04 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Nov 14 | Option Exercise | 3.10 | 5,161 | 15,999 | 210,802 | Nov 16 07:01 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Nov 02 | Sale | 21.45 | 7,000 | 150,162 | 205,641 | Nov 06 07:01 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 27 | Sale | 27.33 | 20,561 | 561,855 | 132,486 | Aug 28 07:01 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 24 | Option Exercise | 17.91 | 4,121 | 73,807 | 157,168 | Aug 28 07:01 PM | | Brinkley David L | Head of Business Dev. | Aug 24 | Sale | 27.50 | 3,483 | 95,783 | 60,241 | Aug 28 07:02 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 24 | Sale | 28.01 | 4,121 | 115,429 | 153,047 | Aug 28 07:01 PM | | Mammen Mathai | SVP, Research & Early Clin Dev | Aug 13 | Sale | 25.74 | 25,000 | 643,461 | 212,285 | Aug 15 07:05 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 07 | Option Exercise | 16.25 | 60,000 | 975,000 | 217,924 | Aug 09 07:00 PM | | Aguiar Michael W | Sr VP, Chief Financial Officer | Aug 07 | Sale | 27.04 | 60,000 | 1,622,400 | 157,924 | Aug 09 07:00 PM | | Brinkley David L | Head of Business Dev. | Aug 03 | Option Exercise | 7.88 | 106,757 | 840,955 | 190,698 | Aug 07 07:03 PM | | Winningham Rick E | Chief Executive Officer | Aug 03 | Option Exercise | 3.10 | 145,161 | 449,999 | 667,007 | Aug 07 07:02 PM | | Brinkley David L | Head of Business Dev. | Aug 03 | Sale | 27.92 | 123,917 | 3,459,763 | 66,781 | Aug 07 07:03 PM | | Winningham Rick E | Chief Executive Officer | Aug 03 | Sale | 27.95 | 75,749 | 2,117,306 | 591,258 | Aug 07 07:02 PM |
|
|
|
|
|
|
